Versant Capital Management, Inc Day One Biopharmaceuticals, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 604 shares of DAWN stock, worth $4,228. This represents 0.0% of its overall portfolio holdings.
Number of Shares
604Holding current value
$4,228% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DAWN
# of Institutions
196Shares Held
76.7MCall Options Held
138KPut Options Held
208K-
Atlas Venture Life Science Advisors, LLC6.43MShares$45 Million14.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$41.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$40.3 Million0.95% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$31.7 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL4.06MShares$28.4 Million0.14% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $514M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...